Table 2 Clinical characteristics of study participants (pSTAT5)

n

15

15

16

-

Age (years)

50.3±9.0

59.7±17.2

61.9±17.0

0.66

Sex (% female)

100%

100%

100%

NA

Duration from onset (years)

-

5.7±10.2^a

14.8±10.9^a

0.064

Duration from diagnosis (years)

-

5.7±7.0

9.8±7.2^b

0.079

BMI

-

25.6±4.6^b

25.3±6.2^b

0.88

Stimulated salivary flow rate

-

7.2±3.1 ml/5 min

1.5±0.9 ml/5 min

6.66 × 10^-9

Schirmer right (mm/5 min)

-

8.0±9.3

5.5±5.9^b

0.69

Schirmer left (mm/5 min)

-

7.9±7.4

6.5±7.0^b

0.61

Anti-SSA

-

11/73.3%

13/86.7%^c

0.39

Anti-SSB

-

2/13.3%

5/33.3%^c

0.21

Seropositive (SSA and/or SSB)

-

11/73.3%

13/86.7%^c

0.39

cMARD

-

5/35.7%^d

4/33.3%^e

0.93

bMARD (anti-TNF)

-

0/0.0%^f

0/0.0%^a

NA

Glucocorticoid

-

3/21.4%^d

1/9.1%^g

0.44

Cyclosporine eye drops

-

3/37.5%^h

3/33.3%^f

0.91

Oral pilocarpine

-

1/14.3%ⁱ

1/12.5%^h

1

Natural tears

-

4/40.0%^j

2/28.6%ⁱ

0.68

Angina pectoris

-

1^b

0^e

0.38

Autoimmune thyroid disease

-

0

2

0.18

Gynaecologic manifestation

-

1^b

0^e

0.38

Anemia

-

2^b

0^e

0.18

Leukopenia

-

1^b

1^e

1

Neutropenia

-

1^b

0^e

0.38

Cancer

-

1^b

1^e

1